Lymphoma & Plasma Cell Disorders
News
ASH expands late-breaking abstract session
An additional presentation has been added to the late-breaking abstract session of the 2018 ASH Annual Meeting. The session was expanded from six...
New Therapies
Immunotherapy may hold the key to defeating virally associated cancers
News
CAR T-cell studies to be presented at ASH
Several studies set to be presented at the 2018 ASH Annual Meeting provide new insights regarding chimeric antigen receptor (CAR) T-cell therapies...
News
Biosimilar deemed equivalent to rituximab in FL
Phase 3 results suggest the biosimilar product CT-P10 is equivalent to rituximab in patients with low-tumor-burden follicular lymphoma (FL)....
News
Elderly NHL patients have higher NRM after HSCT
A retrospective study suggests elderly patients with non-Hodgkin lymphoma (NHL) are more likely to die, but not relapse, within a year of...
News
Americans concerned about cost of cancer care
A recent survey suggests Americans are nearly as worried about the cost of a cancer diagnosis as they are about dying from cancer. The cost of...
From the Journals
Rituximab biosimilar looks equivalent in follicular lymphoma
CT-P10 has been recommended for approval in the U.S. by the FDA’s Oncologic Drugs Advisory Committee.
News
Bortezomib may overcome resistance in WM
Bortezomib may help overcome treatment resistance in patients with Waldenström’s macroglobulinemia (WM) and CXCR4 mutations, according to a new...
News
FDA expands approval of brentuximab vedotin to PTCL
This is the first FDA approval of a treatment for newly-diagnosed PTCL.
News
Quick FDA approval for brentuximab vedotin in PTCL
The U.S.
News
R-CHOP effective as first-line treatment in FL
Long-term data suggest R-CHOP can be effective as first-line treatment for patients with follicular lymphoma (FL). In a phase 2-3 trial,...